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Introduction
The central nervous system (CNS) is among the most important organ systems, integrating
information inputs and coordinating the activity of all other body systems. Like many organ
systems, the CNS is susceptible to infection by pathogenic microorganisms, including many
arboviruses that are considered neurotropic because they are able to achieve robust replication
in neural cells. Neurotropic arboviruses capable of infecting the CNS include members of the
Flaviviridae (e.g., West Nile and Japanese encephalitis viruses), Bunyaviridae (La Cross and
Rift Valley Fever viruses), and Togaviridae (Alphavirus species) families, all RNA viruses that
are maintained in complex life cycles involving a nonhuman primary vertebrate and a primary
arthropod vector [1]. A variety of mechanisms exist to protect the CNS from the entry and
infection of neurotropic viruses, including innate immune responses and multilayer barriers
formed by diverse host cell types [2]. However, many arboviruses gain access to the CNS either
as free virions, within motile infected cells, and/or by using axonal transport mechanisms of
peripheral nerves that directly enter or form synapses within the CNS. Viruses that enter via
the bloodstream must cross CNS endothelial barriers that exhibit unique specializations, collec-
tively termed the blood-brain barrier (BBB).
The Blood-Brain Barrier
The CNS is normally protected from pathogens in the circulation by the BBB. The BBB is a
dynamic interface that limits the passage of molecules and cells from the blood to the brain,
protecting neural cells from injury [3,4]. It is formed by highly specialized brain microvascular
endothelial cells (BMECs) joined by tight (TJ) and adherens junctions (AJ) with associated
pericytes and enveloped by astrocytic endfeet [5]. These TJ and AJ complexes effectively seal
the paracellular space between BMECs, preventing the movement of pathogens and pathogen-
infected cells in the blood into the CNS parenchyma [6]. Disruption of the BBB is a hallmark of
CNS infections and can be caused by both viral factors and the host immune response [2].
Recent research has highlighted how a major family of antiviral cytokines, the interferons
(IFNs), plays multifaceted roles at the BBB during neurotropic viral infections. This review will
summarize recent investigations that have expanded our understanding of how host IFNs
serve to protect the CNS during viral infections.
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Type I IFN
The type I IFNs consist of the ligands IFN-β and 13 IFN-α subtypes, which each signal through
a common IFN-α receptor (IFNAR) that is expressed by nearly all nucleated cells in the body.
Type I IFNs are rapidly induced during viral infection by host detection of pathogen-associated
molecular patterns (PAMPs), and their role in restricting viral pathogenesis has been exten-
sively characterized [7]. These functions include induction of the antiviral state in both infected
and bystander host cells. Type I IFN signaling via the canonical JAK/STAT pathway leads to
the expression of a panoply of interferon stimulated genes (ISGs), many of which are absolutely
essential for restriction of viral infections and effective viral clearance [7,8]. In addition to the
traditional antiviral functions of type I IFNs, however, a growing body of research has estab-
lished critical functions for type I IFN at the BBB during inflammatory diseases of the CNS.
The first indications that type I IFNs could modulate BBB function were discovered in the
context of CNS autoimmunity. In animal models and in vitro BBB cultures consisting of
BMECs and astrocytes grown in transwell systems, treatment with type I IFNs decreases BBB
permeability, enhances TJ integrity, and limits the migration of leukocytes across the BBB into
the CNS parenchyma [9–11], effects that contribute to the efficacy of IFN-β as a treatment for
the CNS autoimmune disease multiple sclerosis. However, although type I IFNs have been
known to preserve BBB integrity in the context of autoimmunity for some time, the potential
effects of these antiviral cytokines on the BBB during neurotropic viral infections have only
recently been addressed.
Indeed, recent work has established a novel antiviral function for type I IFNs at the BBB.
The induction of type I IFN expression following detection of viral pathogens such as West
Nile virus (WNV) acts directly on BBB endothelium to preserve TJ formation and limit BBB
permeability [11]. This effect is mediated by preferential activation of the cytoskeletal regula-
tory GTPase Rac1, which is known to enhance endothelial barrier function. This effect prevents
and/or reverses the activation of the opposing GTPase RhoA, whose activation downstream of
inflammatory signals leads to loss of TJ integrity and barrier function [11,12]. In addition, type
I IFNs act indirectly to preserve BBB integrity by limiting the expression of barrier-disrupting
inflammatory cytokines, including TNF-α and IL-1β [8,11]. While the relative contributions of
circulating serum IFNs versus local CNS IFN expression to these processes remains unclear, it
is likley that IFN signalling on both sides of the BBB works to preserve barrier integrity during
neurotropic viral infection [2,11].
Type II IFN
The type II IFN family consists solely of IFN-γ, an inflammatory cytokine that signals through
the IFN-γ receptor (IFNGR). In contrast to type I IFNs, type II IFN is most associated with
adaptive immune responses. The secretion of IFN-γ by Natural Killer (NK) cells and activated
T cells is a major signal for the recruitment and activation of leukocytes to sites of infection.
While the actions of IFN-γ at the BBB have often been considered to be secondary conse-
quences of its role in leukocyte recruitment, vascular endothelia can also respond directly to
IFN-γ stimulation. Addition of IFN-γ to vascular endothelia in vitro dysregulates barrier func-
tion, leading to enhanced permeability [11]. Recent research has identified IFN-γ as a driver of
BBB permeability in the context of CNS infections, including pneumococcal meningitis [13]
and rabies virus (RabV) infection [14]. Putative mechanisms for direct BBB dysregulation by
IFN-γ include the down-regulation and/or internalization of TJ proteins [14,15].
In addition to direct effects on BBB endothelium, the enhancement of leukocyte trafficking
and activation by IFN-γ also serves to disrupt BBB function by promoting the expression of
other inflammatory cytokines and chemokines. Most notably, IFN-γ expression in response to
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CNS infections is a potent inducer of the lymphocyte chemoattractant CXCL10. IFN-γ-medi-
ated stimulation of CXCL10 expression enhances the recruitment of yet more IFN-γ–express-
ing T-lymphocytes to sites of infection, establishing a feedforward mechanism by which
increasing numbers of inflammatory cells traffic to sites of infection and produce inflammatory
mediators that perturb BBB function. This IFN-γ/CXCL10 axis is a major source of BBB break-
down and neuroinflammation during several CNS infections, including those caused by RabV
[14] and Human T-lymphotropic virus-1 (HTLV-1) [16]. While the disruption of the BBB due
to inflammation can be a route of access for circulating pathogens and a source of tissue injury,
it is often also necessary for effective cell-mediated immunity in the CNS and complete patho-
gen clearance [2].
Type III IFN
The recently classified type III IFNs are composed of three IFN-λ subtypes, each of which sig-
nal through a receptor complex made up of the IFN-λ receptor (IFNLR1) and an IL10Rβ sub-
unit. Though, like type I IFNs, they are induced by host detection of PAMPs, the expression of
type III IFNs is primarily restricted to tissue barriers, including intestinal, airway, vaginal, and
skin epithelia [17]. Though IFN-λ signals through similar mechanisms as type I IFNs, recent
research has demonstrated that IFN-λ plays essential, nonredundant antiviral functions in bar-
rier epithelia in the context of gastrointestinal infections [18–20]. However, though the roles of
IFN-λ at epithelial barriers during viral infections have been increasingly well characterized, it
has remained unclear whether IFN-λ also signals at endothelial barriers.
In a recent study by our group and others, we showed that IFNLR1 is expressed on neuro-
vascular cells, including BMECs and astrocytes [21]. In the setting of WNV infection, IFN-λ
signalling at the BBB served to preserve BBB function by enhancing TJ integrity, thereby limit-
ing the neuroinvasive potential of WNV. This effect was observed in the absence of direct anti-
viral effects of IFN-λ on neurons or other cells normally targeted by WNV. IFN-λ-mediated
effects on BBB function occur through poorly understood mechanisms that are independent of
protein synthesis and STAT1 activation. In addition, Ifnlr1-/- exhibited normal adaptive
immune responses following WNV infection, in contrast to mice deficient in type I IFN signal-
ling [8]. Thus, though IFN-λ preserves BBB integrity through similar mechanisms as type I
IFN during WNV infection, the restriction of IFNLR1 to tissue barriers and the specificity of
IFN-λ signaling to effects on the BBB during WNV infection make IFN-λ an exciting potential
therepeutic option for neuroinvasive infections and other diseases that involve breakdown of
the BBB, including CNS autoimmunity.
Concluding Remarks
Viral infections of the CNS remain an important cause of morbidity and mortality worldwide,
primarily due to the effects of virus invasion and/or to pathologic CNS entry of immune cells.
Here we have highlighted some of the distinct signaling pathways whereby interferons may
regulate virus versus immune cell entry into the CNS at the BBB at lumenal and abluminal sur-
faces (see Fig 1). The separation of these processes appears to be an adaptive response that
allows the CNS to protect itself from infection with virus while, at the same time, promoting
viral clearance. It is clear that the elucidation of factors and pathways that control these
mechanisms is essential for the development of strategies to limit CNS infections while pro-
moting normal immune function. However, the potential for coincidental signaling of these
pathways in certain individuals may ultimately provide the explanation for how viruses may
modulate barrier function such that immune privilege is compromised, triggering CNS auto-
immunity. Indeed, the interactions between type II IFN–expressing immune cells with type I
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IFN–expressing BMECs suggest that opposing signals may converge on the BBB. The kinetics
of this process may determine whether the BBB remains closed or opens, as the presence of
virus at the BBB may be temporary. Further studies are needed to define essential mechanisms
of innate immunity at the BBB, the impact of viral infections on converging signaling path-
ways, and their links to neuropathologic processes.
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